| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pulmonary Disease, Chronic Obstructive | 19 | 2018 | 3832 | 2.28 | Why? |
| Hypercapnia | 3 | 2017 | 172 | 1.85 | Why? |
| Noninvasive Ventilation | 7 | 2020 | 2329 | 1.78 | Why? |
| Diaphragm | 3 | 2018 | 232 | 1.66 | Why? |
| Positive-Pressure Respiration | 6 | 2018 | 1160 | 1.62 | Why? |
| Bronchiectasis | 9 | 2018 | 312 | 1.42 | Why? |
| Breathing Exercises | 3 | 2018 | 118 | 1.37 | Why? |
| Inhalation | 6 | 2018 | 86 | 1.34 | Why? |
| Exercise Tolerance | 2 | 2017 | 634 | 0.94 | Why? |
| Respiratory Muscles | 3 | 2018 | 116 | 0.94 | Why? |
| Exercise Test | 3 | 2017 | 911 | 0.93 | Why? |
| Electromyography | 3 | 2018 | 278 | 0.92 | Why? |
| Respiration | 2 | 2017 | 729 | 0.91 | Why? |
| Lung | 15 | 2020 | 31049 | 0.84 | Why? |
| Methacholine Chloride | 1 | 2018 | 14 | 0.76 | Why? |
| Obesity Hypoventilation Syndrome | 1 | 2018 | 20 | 0.74 | Why? |
| Muscle, Smooth | 1 | 2018 | 67 | 0.72 | Why? |
| Work of Breathing | 2 | 2017 | 86 | 0.72 | Why? |
| Tiotropium Bromide | 1 | 2018 | 46 | 0.71 | Why? |
| TRPC Cation Channels | 1 | 2017 | 7 | 0.71 | Why? |
| beta Catenin | 1 | 2018 | 78 | 0.70 | Why? |
| Airway Remodeling | 1 | 2018 | 111 | 0.68 | Why? |
| Respiratory Center | 1 | 2017 | 18 | 0.68 | Why? |
| Therapy, Computer-Assisted | 1 | 2017 | 39 | 0.67 | Why? |
| Myocytes, Smooth Muscle | 1 | 2018 | 127 | 0.66 | Why? |
| Forced Expiratory Volume | 7 | 2018 | 632 | 0.65 | Why? |
| Extracellular Matrix | 1 | 2018 | 189 | 0.65 | Why? |
| Calcium Signaling | 1 | 2017 | 133 | 0.63 | Why? |
| Muscarinic Antagonists | 1 | 2018 | 176 | 0.62 | Why? |
| Benzofurans | 1 | 2017 | 91 | 0.62 | Why? |
| Lipocalin-2 | 1 | 2017 | 156 | 0.61 | Why? |
| Hospitals, Special | 1 | 2020 | 523 | 0.60 | Why? |
| Oxygen Inhalation Therapy | 2 | 2020 | 3629 | 0.59 | Why? |
| Quality of Life | 9 | 2018 | 9820 | 0.58 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2017 | 253 | 0.56 | Why? |
| Doxorubicin | 1 | 2017 | 313 | 0.56 | Why? |
| Myocytes, Cardiac | 3 | 2018 | 804 | 0.56 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 511 | 0.55 | Why? |
| Protective Agents | 1 | 2017 | 250 | 0.54 | Why? |
| Endoplasmic Reticulum | 1 | 2017 | 430 | 0.54 | Why? |
| Respiratory Mechanics | 1 | 2018 | 585 | 0.53 | Why? |
| Resistance Training | 1 | 2017 | 273 | 0.53 | Why? |
| Ventilator-Induced Lung Injury | 1 | 2017 | 260 | 0.52 | Why? |
| Mobile Health Units | 1 | 2020 | 741 | 0.51 | Why? |
| Influenza B virus | 2 | 2018 | 815 | 0.50 | Why? |
| Respiratory Insufficiency | 3 | 2020 | 7301 | 0.50 | Why? |
| Carbon Dioxide | 2 | 2017 | 917 | 0.50 | Why? |
| Continuous Positive Airway Pressure | 2 | 2020 | 1187 | 0.49 | Why? |
| Connective Tissue Diseases | 1 | 2014 | 187 | 0.45 | Why? |
| Bronchi | 1 | 2018 | 1048 | 0.44 | Why? |
| Air Microbiology | 1 | 2020 | 1322 | 0.40 | Why? |
| Lamiaceae | 2 | 2018 | 29 | 0.37 | Why? |
| Software | 2 | 2017 | 2501 | 0.36 | Why? |
| Translating | 2 | 2018 | 80 | 0.34 | Why? |
| Dyspnea | 2 | 2017 | 3847 | 0.32 | Why? |
| Spirometry | 7 | 2017 | 524 | 0.31 | Why? |
| Bronchodilator Agents | 4 | 2018 | 444 | 0.30 | Why? |
| Home Care Services | 1 | 2017 | 1351 | 0.30 | Why? |
| Respiratory Function Tests | 5 | 2018 | 1755 | 0.29 | Why? |
| Exhalation | 3 | 2018 | 441 | 0.29 | Why? |
| China | 15 | 2020 | 50654 | 0.27 | Why? |
| Flavonoids | 2 | 2018 | 492 | 0.25 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.25 | Why? |
| Lung Diseases, Interstitial | 1 | 2014 | 1476 | 0.24 | Why? |
| Predictive Value of Tests | 4 | 2018 | 9537 | 0.22 | Why? |
| Surveys and Questionnaires | 4 | 2018 | 43792 | 0.22 | Why? |
| Pressure | 2 | 2017 | 289 | 0.22 | Why? |
| Membrane Potential, Mitochondrial | 2 | 2018 | 102 | 0.21 | Why? |
| Reproducibility of Results | 4 | 2018 | 11304 | 0.21 | Why? |
| Dogs | 2 | 2018 | 2529 | 0.20 | Why? |
| Disease Models, Animal | 4 | 2020 | 10998 | 0.20 | Why? |
| Dose-Response Relationship, Drug | 3 | 2018 | 3776 | 0.20 | Why? |
| Heart Diseases | 1 | 2017 | 3503 | 0.20 | Why? |
| Male | 36 | 2020 | 367725 | 0.20 | Why? |
| Vital Capacity | 2 | 2018 | 399 | 0.19 | Why? |
| Biomarkers | 3 | 2017 | 23361 | 0.19 | Why? |
| Proteobacteria | 1 | 2018 | 36 | 0.19 | Why? |
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 45 | 0.18 | Why? |
| Maximal Respiratory Pressures | 1 | 2017 | 16 | 0.18 | Why? |
| Muscle Strength | 2 | 2018 | 317 | 0.18 | Why? |
| Hemangioma, Capillary | 1 | 2018 | 17 | 0.18 | Why? |
| Sputum | 2 | 2018 | 1720 | 0.18 | Why? |
| Lung Volume Measurements | 1 | 2018 | 115 | 0.18 | Why? |
| Metered Dose Inhalers | 1 | 2018 | 46 | 0.18 | Why? |
| Formoterol Fumarate | 1 | 2018 | 61 | 0.18 | Why? |
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 29 | 0.18 | Why? |
| Pulmonary Embolism | 2 | 2016 | 4775 | 0.18 | Why? |
| Middle Aged | 29 | 2020 | 270681 | 0.18 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.18 | Why? |
| Glycopyrrolate | 1 | 2018 | 51 | 0.18 | Why? |
| Cytoprotection | 1 | 2017 | 44 | 0.17 | Why? |
| Humans | 57 | 2020 | 930598 | 0.17 | Why? |
| Extracellular Matrix Proteins | 1 | 2018 | 95 | 0.17 | Why? |
| Prospective Studies | 7 | 2018 | 43301 | 0.17 | Why? |
| Phosphorylation | 2 | 2018 | 1060 | 0.17 | Why? |
| Oleic Acid | 1 | 2017 | 43 | 0.17 | Why? |
| Virus Diseases | 1 | 2015 | 3779 | 0.17 | Why? |
| Rats, Sprague-Dawley | 2 | 2018 | 987 | 0.17 | Why? |
| Heme Oxygenase-1 | 1 | 2018 | 90 | 0.17 | Why? |
| X-Ray Microtomography | 1 | 2017 | 115 | 0.17 | Why? |
| B-Cell Activating Factor | 1 | 2016 | 36 | 0.17 | Why? |
| Cholecystectomy | 1 | 2019 | 198 | 0.16 | Why? |
| Cytochrome P-450 CYP2C9 | 1 | 2016 | 25 | 0.16 | Why? |
| Translations | 1 | 2017 | 153 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| GTP-Binding Proteins | 1 | 2017 | 132 | 0.16 | Why? |
| Lung Neoplasms | 3 | 2018 | 3228 | 0.16 | Why? |
| Aged | 21 | 2020 | 215776 | 0.16 | Why? |
| Vitamin K Epoxide Reductases | 1 | 2016 | 32 | 0.16 | Why? |
| Saponins | 1 | 2018 | 171 | 0.16 | Why? |
| Neuraminidase | 1 | 2018 | 289 | 0.16 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.16 | Why? |
| Myocardial Reperfusion Injury | 1 | 2018 | 129 | 0.16 | Why? |
| Female | 32 | 2020 | 380317 | 0.15 | Why? |
| Myocardial Contraction | 1 | 2017 | 123 | 0.15 | Why? |
| Equipment Design | 2 | 2017 | 3095 | 0.15 | Why? |
| Triterpenes | 1 | 2018 | 199 | 0.15 | Why? |
| Thyroid Hormones | 1 | 2017 | 213 | 0.15 | Why? |
| Hospital Costs | 1 | 2018 | 274 | 0.15 | Why? |
| Protein Transport | 1 | 2017 | 487 | 0.15 | Why? |
| Tidal Volume | 1 | 2018 | 565 | 0.15 | Why? |
| Ribosomes | 1 | 2017 | 200 | 0.15 | Why? |
| Venous Thromboembolism | 1 | 2014 | 4273 | 0.15 | Why? |
| Factor Analysis, Statistical | 1 | 2017 | 538 | 0.15 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.15 | Why? |
| Treatment Outcome | 7 | 2018 | 51732 | 0.15 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 372 | 0.15 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.14 | Why? |
| Saccharomyces cerevisiae | 1 | 2017 | 339 | 0.14 | Why? |
| Antibodies, Antinuclear | 1 | 2016 | 234 | 0.14 | Why? |
| Meta-Analysis as Topic | 2 | 2020 | 1289 | 0.14 | Why? |
| Tobacco | 1 | 2016 | 274 | 0.14 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| Carrier Proteins | 1 | 2017 | 513 | 0.13 | Why? |
| NF-E2-Related Factor 2 | 1 | 2018 | 373 | 0.13 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.13 | Why? |
| Cardiotoxicity | 1 | 2017 | 365 | 0.13 | Why? |
| Pulmonary Medicine | 1 | 2020 | 706 | 0.13 | Why? |
| Breath Tests | 1 | 2017 | 338 | 0.13 | Why? |
| Adenoviridae Infections | 1 | 2014 | 150 | 0.13 | Why? |
| Receptors, Cell Surface | 1 | 2017 | 586 | 0.13 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.12 | Why? |
| Advisory Committees | 1 | 2020 | 1418 | 0.12 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.12 | Why? |
| Apoptosis | 3 | 2018 | 2335 | 0.12 | Why? |
| Angiography | 1 | 2014 | 301 | 0.12 | Why? |
| Cigarette Smoking | 1 | 2016 | 337 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.12 | Why? |
| Animals | 10 | 2020 | 78931 | 0.12 | Why? |
| RNA Virus Infections | 1 | 2014 | 231 | 0.12 | Why? |
| Rivaroxaban | 1 | 2016 | 467 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.12 | Why? |
| Language | 1 | 2017 | 655 | 0.12 | Why? |
| Educational Status | 1 | 2018 | 1451 | 0.11 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.11 | Why? |
| Respiratory Therapy | 1 | 2018 | 918 | 0.11 | Why? |
| Image Processing, Computer-Assisted | 2 | 2017 | 1383 | 0.11 | Why? |
| Chemokine CXCL10 | 1 | 2015 | 565 | 0.11 | Why? |
| Pharynx | 1 | 2018 | 1544 | 0.11 | Why? |
| Nursing Staff | 1 | 2018 | 542 | 0.11 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.10 | Why? |
| Walking | 1 | 2015 | 442 | 0.10 | Why? |
| Base Sequence | 1 | 2018 | 3581 | 0.10 | Why? |
| Psychometrics | 1 | 2017 | 1269 | 0.10 | Why? |
| Respiratory Mucosa | 1 | 2018 | 1522 | 0.10 | Why? |
| Protein Interaction Maps | 1 | 2017 | 1333 | 0.10 | Why? |
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 896 | 0.10 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.10 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.09 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.09 | Why? |
| Enoxaparin | 1 | 2016 | 1064 | 0.09 | Why? |
| Europe | 3 | 2020 | 12702 | 0.09 | Why? |
| Adult | 20 | 2020 | 244371 | 0.09 | Why? |
| Asthma | 2 | 2018 | 4383 | 0.09 | Why? |
| Professional Role | 1 | 2018 | 1280 | 0.09 | Why? |
| Carcinoma, Squamous Cell | 1 | 2017 | 902 | 0.09 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.09 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.09 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.09 | Why? |
| Administration, Inhalation | 3 | 2018 | 1647 | 0.09 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.08 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.08 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.08 | Why? |
| Symptom Assessment | 2 | 2017 | 4967 | 0.08 | Why? |
| Total Lung Capacity | 1 | 2005 | 40 | 0.08 | Why? |
| Mice | 4 | 2020 | 21357 | 0.08 | Why? |
| Pulmonary Ventilation | 1 | 2007 | 152 | 0.08 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.07 | Why? |
| Ventilators, Mechanical | 1 | 2017 | 2193 | 0.07 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.07 | Why? |
| Anxiety Disorders | 1 | 2017 | 2290 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Signal Transduction | 2 | 2018 | 7207 | 0.07 | Why? |
| Adrenal Cortex Hormones | 2 | 2018 | 6537 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.07 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.07 | Why? |
| Research | 1 | 2017 | 2115 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.07 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 5002 | 0.06 | Why? |
| Pharmaceutical Preparations | 1 | 2018 | 1897 | 0.06 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.06 | Why? |
| Prevalence | 2 | 2015 | 25773 | 0.06 | Why? |
| Severity of Illness Index | 6 | 2020 | 48226 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Severe Acute Respiratory Syndrome | 4 | 2006 | 12361 | 0.05 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.05 | Why? |
| Acids, Carbocyclic | 1 | 2019 | 27 | 0.05 | Why? |
| Antibodies, Viral | 4 | 2020 | 51949 | 0.05 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.05 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.05 | Why? |
| Cyclopentanes | 1 | 2019 | 55 | 0.05 | Why? |
| Specific Pathogen-Free Organisms | 1 | 2020 | 358 | 0.05 | Why? |
| Transduction, Genetic | 1 | 2020 | 273 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Plant Components, Aerial | 1 | 2018 | 12 | 0.05 | Why? |
| Sickness Impact Profile | 1 | 2018 | 56 | 0.05 | Why? |
| Receptors for Activated C Kinase | 1 | 2017 | 5 | 0.05 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.05 | Why? |
| STAT1 Transcription Factor | 1 | 2020 | 313 | 0.04 | Why? |
| Residual Volume | 1 | 2017 | 45 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Young Adult | 7 | 2018 | 93724 | 0.04 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.04 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.04 | Why? |
| Cell Hypoxia | 1 | 2018 | 141 | 0.04 | Why? |
| Gryllidae | 1 | 2017 | 3 | 0.04 | Why? |
| Mice, Inbred BALB C | 2 | 2020 | 5814 | 0.04 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 5993 | 0.04 | Why? |
| Tertiary Lymphoid Structures | 1 | 2016 | 6 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Travel | 1 | 2015 | 7220 | 0.04 | Why? |
| Licensure | 1 | 2018 | 144 | 0.04 | Why? |
| Phantoms, Imaging | 1 | 2017 | 146 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2018 | 22116 | 0.04 | Why? |
| Influenza, Human | 2 | 2018 | 10779 | 0.04 | Why? |
| Herpesvirus 4, Human | 1 | 2019 | 387 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Antibody Specificity | 1 | 2020 | 1328 | 0.04 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 347 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2018 | 606 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.04 | Why? |
| Certification | 1 | 2018 | 261 | 0.04 | Why? |
| Head | 1 | 2017 | 206 | 0.04 | Why? |
| Oseltamivir | 1 | 2019 | 583 | 0.04 | Why? |
| Parainfluenza Virus 1, Human | 1 | 2014 | 71 | 0.04 | Why? |
| Mice, Knockout | 1 | 2020 | 1815 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2017 | 53120 | 0.04 | Why? |
| Parainfluenza Virus 3, Human | 1 | 2014 | 67 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.03 | Why? |
| Guanidines | 1 | 2019 | 499 | 0.03 | Why? |
| Culture | 1 | 2018 | 370 | 0.03 | Why? |
| Internationality | 2 | 2018 | 3297 | 0.03 | Why? |
| Eosinophilia | 1 | 2018 | 292 | 0.03 | Why? |
| Immunoglobulin E | 1 | 2018 | 557 | 0.03 | Why? |
| Anticoagulants | 1 | 2016 | 9563 | 0.03 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.03 | Why? |
| Influenza A Virus, H7N9 Subtype | 1 | 2019 | 415 | 0.03 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.03 | Why? |
| Diagnostic Self Evaluation | 1 | 2018 | 394 | 0.03 | Why? |
| Inservice Training | 1 | 2018 | 477 | 0.03 | Why? |
| Respirovirus Infections | 1 | 2014 | 90 | 0.03 | Why? |
| Vitamin K | 1 | 2016 | 263 | 0.03 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2015 | 8843 | 0.03 | Why? |
| Adolescent | 4 | 2018 | 86841 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2014 | 21571 | 0.03 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.03 | Why? |
| Models, Animal | 1 | 2017 | 788 | 0.03 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2018 | 88759 | 0.03 | Why? |
| Depression | 1 | 2017 | 14116 | 0.03 | Why? |
| Molecular Structure | 1 | 2018 | 1539 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.03 | Why? |
| Spleen | 1 | 2016 | 877 | 0.03 | Why? |
| Emergency Treatment | 1 | 2018 | 719 | 0.03 | Why? |
| Hand | 1 | 2017 | 449 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2018 | 1136 | 0.03 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.03 | Why? |
| Asia | 1 | 2018 | 2399 | 0.03 | Why? |
| Nitric Oxide | 1 | 2018 | 769 | 0.03 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.03 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Bronchoscopy | 1 | 2018 | 991 | 0.03 | Why? |
| Interferon-gamma | 1 | 2020 | 2711 | 0.03 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2020 | 5542 | 0.02 | Why? |
| Cryoelectron Microscopy | 1 | 2017 | 2372 | 0.02 | Why? |
| Picornaviridae Infections | 1 | 2014 | 544 | 0.02 | Why? |
| Global Health | 3 | 2017 | 13911 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Comorbidity | 3 | 2018 | 34796 | 0.02 | Why? |
| Administration, Oral | 1 | 2016 | 2340 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Healthy Volunteers | 1 | 2014 | 1444 | 0.02 | Why? |
| Hypertension, Pulmonary | 1 | 2018 | 970 | 0.02 | Why? |
| Immunoglobulin M | 3 | 2016 | 9091 | 0.02 | Why? |
| Rhinovirus | 1 | 2014 | 979 | 0.02 | Why? |
| Physician-Patient Relations | 1 | 2018 | 1266 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.02 | Why? |
| Adenoviridae | 1 | 2014 | 1151 | 0.02 | Why? |
| Smoking Cessation | 1 | 2016 | 826 | 0.02 | Why? |
| Antioxidants | 1 | 2018 | 1593 | 0.02 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Attitude to Health | 1 | 2018 | 2002 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.02 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.02 | Why? |
| Genotype | 1 | 2016 | 4697 | 0.02 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 393 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| Surgical Procedures, Operative | 1 | 2018 | 2662 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Influenza A virus | 1 | 2014 | 2234 | 0.01 | Why? |
| United States | 2 | 2020 | 46150 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Community-Acquired Infections | 1 | 2014 | 2328 | 0.01 | Why? |
| B-Lymphocytes | 1 | 2016 | 4418 | 0.01 | Why? |
| SARS Virus | 1 | 2005 | 13021 | 0.01 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2005 | 552 | 0.01 | Why? |
| Venous Thrombosis | 1 | 2016 | 2739 | 0.01 | Why? |
| Tomography, X-Ray Computed | 2 | 2017 | 25144 | 0.01 | Why? |
| Critical Care | 1 | 2003 | 14081 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Convalescence | 1 | 2006 | 2829 | 0.01 | Why? |
| Coinfection | 1 | 2014 | 6820 | 0.01 | Why? |
| Neutralization Tests | 1 | 2006 | 6698 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2006 | 9893 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 7868 | 0.01 | Why? |
| Antiviral Agents | 1 | 2019 | 41703 | 0.00 | Why? |